Needham’s Buy Rating Puts LB Pharmaceuticals’ 2027 Trial Catalyst in the Spotlight
Needham’s Buy initiation highlights LB Pharmaceuticals ahead of the pivotal NOVA-2 schizophrenia readout expected in the first half of 2027.
Pfizer’s Tilrekimig Advances to Phase 3 as Investors Seek New Growth Drivers
Pfizer’s tilrekimig met its Phase 2 goal and is advancing to Phase 3, but the program remains an opportunity—not proof of approval.
AbbVie’s JUVMO Approval Puts 41% Undervaluation Thesis in Focus
AbbVie’s JUVMO approval strengthens its pipeline narrative, while Simply Wall St’s 41% undervaluation estimate remains a forecast—not confir…
United Therapeutics Jumps 13.2% After FDA Accepts Supplemental Tyvaso Application
United Therapeutics shares traded up 13.2% after FDA acceptance of a supplemental Tyvaso application and an announced buyback.
Q32 Bio Slides 13.2% as Oppenheimer Defends Rating Despite Bempikibart Data Concerns
Q32 Bio fell 13.2% as investors questioned bempikibart’s efficacy, while Oppenheimer maintained its rating and highlighted data durability.
AbbVie’s Rinvoq Vitiligo Data Set Up Q4 FDA Catalyst for ABBV Investors
Rinvoq’s promising vitiligo results and expected Q4 2026 FDA decision add a potential growth catalyst, though dividend concerns remain.
Wave Life Sciences Shares Rise as FDA Confirms Registrational Pathway for WVE-006
FDA alignment on WVE-006 trial design gives Wave Life Sciences a clearer regulatory path, but execution and clinical validation remain ahead…
Q32 Bio Stock Falls 13.2% as Oppenheimer Stands by Rating Despite Trial-Data Concerns
Q32 Bio sharply underperformed biotech peers as investors questioned bempikibart efficacy, while Oppenheimer pointed to the data's durabilit…
PolyPid Regains European Rights to D-PLEX100: What It Means for PYPD’s Strategy
PolyPid’s return of European rights to D-PLEX100 may expand partnership options and reshape the valuation narrative for $PYPD.
Outlook Therapeutics Seeks CMS Reimbursement Code Ahead of LYTENAVA Launch
Outlook Therapeutics’ CMS reimbursement application marks a key commercial milestone for LYTENAVA and $OTLK ahead of its planned 2026 U.S. l…
Merck’s Positive Phase 2 HS Data Offer a Glimpse Beyond Oncology
Merck’s positive Phase 2 hidradenitis suppurativa data could broaden investor focus beyond its oncology franchise.
Praxis Precision Medicine Options Activity Builds Ahead of Two FDA Decisions
Praxis Precision Medicine is seeing elevated options activity as traders position around two FDA decisions, analyst targets, and the EMERALD…